Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Pharmaceutical

Catalyst Pharmaceuticals

Patrick J. McEnany 

Gary Ingenito

Jeff Del Carmen

Preethi Sundaram

Steven R. Miller

Alicia Grande

Brian Elsbernd

The Medical Affairs and Patient Advocacy team at Catalyst Pharmaceuticals plays a crucial role in ensuring that the company's innovative therapies align with patient needs and regulatory requirements. This team conducts scientific education and communication activities to support healthcare professionals and patients, and it advocates for patient-centered initiatives, ensuring that the voices of those affected by rare diseases are heard in the development and delivery of novel treatments. By fostering collaboration between medical, regulatory, and patient communities, this team helps to enhance access to FIRDAPSE® and future therapies while advancing the company’s mission of improving patient outcomes.

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team

Medical Affairs and Patient Advocacy

About

Team members

Other teams at Catalyst Pharmaceuticals

Board and Governance

Leadership Team